ReviewCurrent cardiology reports2020
Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020.
Review in Current cardiology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.Frontiers in medicine · 2022Pooled it
- Idiopathic recurrent pericarditis in children: a tertiary care cohort highlighting the emergence and effectiveness of interleukin-1 blockade.European journal of pediatrics · 2026Article
- Autoimmune Pericarditis: Diagnosis and New Therapeutics.Current cardiology reports · 2025Review
- Comparative Efficacy and Safety of Colchicine and Anti-Interleukin-1 Agents in Recurrent Pericarditis: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials.Journal of the American Heart Association · 2025Review
- A Comprehensive Clinical Evaluation of Rilonacept in the Treatment of Recurrent Pericarditis: A Systematic Review.Journal of inflammation research · 2025Review
- The efficacy of a single-dose anakinra injection during disease attack in pediatric familial Mediterranean fever.Rheumatology international · 2024Article
- Anakinra-Dependent Recurrent Pericarditis: The Role of the R202Q Variant of the MEFV Gene.Journal of clinical medicine · 2024Article
- Recurrent Pericarditis and Paradigm Shift in Cardiovascular Imaging and Targeted Therapeutics.JACC. Advances · 2024Review
- Interleukin-1 Blockers: A Paradigm Shift in the Treatment of Recurrent Pericarditis.Life (Basel, Switzerland) · 2024Review
- Clinical Utility of Rilonacept for the Treatment of Recurrent Pericarditis: Design, Development, and Place in Therapy.Drug design, development and therapy · 2024Review
- Pericarditis Management in Individuals Contemplating Pregnancy, Currently Pregnant, or Breastfeeding.Current cardiology reports · 2023Review
- Rilonacept and Anakinra in Recurrent Pericarditis: A Systematic Review and Meta-Analysis.Cureus · 2022Review
- Review
- The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease.International journal of molecular sciences · 2022Review
- Management of Idiopathic Viral Pericarditis in the Pediatric Population.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?Frontiers in pediatrics · 2022Article
- Autoinflammatory Diseases and Cytokine Storms-Imbalances of Innate and Adaptative Immunity.International journal of molecular sciences · 2021Review
- Emerging Therapies for Recurrent Pericarditis: Interleukin-1 inhibitors.Journal of the American Heart Association · 2021Review
- A case report: symptomatic pericarditis post-COVID-19 vaccination.European heart journal. Case reports · 2021Article
- Inflamed Colon and Pericardium: A Rare Combination of Colitis and Recurrent Pericarditis.JACC. Case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances have shown impressive results by anti-interleukin 1 (IL-1) agents in refractory idiopathic recurrent pericarditis. PURPOSE OF REVIEW: We critically discuss the current state of the art of therapy of relapsing pericarditis, with a focus on new pharmacological approaches and on specific clinical settings such as pregnancy, pediatric patients, and secondary forms of relapsing pericarditis. RECENT
findingsAntagonism of the IL-1 is highly effective in idiopathic recurrent pericarditis with autoinflammatory features. Currently, available anti-IL-1 agents are anakinra and canakinumab. Rilonacept is another IL-1 antagonist, currently studied in the phase-3 clinical trial RHAPSODY. Available data suggest similar efficacy and safety profiles of these three agents, although only anakinra has been tested in randomized clinical trials. These agents have slightly different pharmacological properties, being canakinumab a specific IL-1ß antagonist while anakinra and rilonacept are unselective IL-1α and IL-1ß blockers. To date, there is no evidence that specificity against IL-1ß affects safety and efficacy in patients with relapsing pericarditis, although it has been proposed that unspecific blockage might be useful in severe disease. Anakinra is the first anti-IL-1 agent with well-documented efficacy and safety in adult and pediatric patients with idiopathic relapsing pericarditis. Other anti-IL-1 agents are currently under study. Future research should clarify the optimal duration of therapy and tapering schedule of treatment with these agents. Moreover, biomarkers would be required to understand which patients will benefit from early administration of IL-1 blockers due to refractoriness to conventional therapy and which others will suffer from recurrences during the tapering of these agents. Lastly, future studies should focus on the subjects with the autoimmune or the pauci-inflammatory phenotype of idiopathic refractory pericarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.